Xin Lang Cai Jing·2026-02-05 08:34Core Viewpoint - Fosun Pharma's subsidiary has received acceptance for the drug application of Fumainin® (Luwomeitini tablets) for new indications, which is now under priority review by the National Medical Products Administration [1] Group 1: Drug Development and Approval - The drug has been approved for two indications in China as of February 5, 2026, with one additional application accepted and two others in clinical trial stages [1] - The total R&D investment for this drug by the group is approximately 663 million yuan by December 2025 [1] Group 2: Market Potential - The global sales for MEK1/2 selective inhibitors are projected to be around 2.068 billion USD in 2024 [1] - Commercialization of the new indications is contingent upon obtaining regulatory approval, but the current acceptance does not impact the company's performance at this stage [1]